Introduction {#sec1}
============

Oral cavity carcinoma was a common malignancy amongst patients with head and neck carcinoma \[[@B1]\]. Researchers found that alcohol and cigarettes consumption as well as human papilloma virus infection, diet, and genetic factors could possibly induce abnormal gene expression, thus leading to the occurrence and development of oral cancers \[[@B2],[@B3]\]. Differing from other cancers like breast, lung, stomach, and kidney cancer, which were susceptible to neoplasm metastasis, local progression, and lymph node involvement of oral cancer was limited \[[@B4]\]. Presently, the primary treatments for oral cancer consisted of surgery, chemotherapy, drug therapy, and radiotherapy \[[@B5]\]. These treatments could improve the prognosis, but late discovery and distant metastases contributed to the relatively high morbidity and mortality rates in oral cancer patients \[[@B6]--[@B8]\]. Therefore, it was vital to improve the accuracy of early diagnosis of oral cancer and to find potential factors that may serve as targets for drug therapy.

Highly conserved amongst various eucaryon, miRNA acted as regulators of gene expression by binding to or repressing mRNAs during transcriptional or translational process \[[@B9]\]. Aberrant miRNA expression has been regarded as common features of cancer development \[[@B10]\]. According to the study of Liborio-Kimura et al. \[[@B11]\], *miR-494* reduced the proliferation of oral cancer cells by repressing the expression of HOXA10. Here, we focus on the functional analysis of *miR-30a-5p*. Altered expression of miR-30a-5p has been reported in colon cancer, glioma, and hepatocellular cancer \[[@B12]--[@B14]\]. Through targetting DTL (denticle-less protein homolog), *miR-30a-5p* suppressed the tumor growth in colon carcinoma \[[@B15]\]. In glioma cells, *miR-30a-5p* negative regulated SEPT7 and promoted cell proliferation and invasion \[[@B16]\]. However, mechanism of *miR-30a-5p* in oral cancer had never been validated yet.

Fibroblast activation protein (FAP) was a homodimer integral membrane gelatinase belonging to the serine protease family. Its aberrant expression had been suggested as a carcinogenic marker \[[@B6],[@B15]--[@B17]\]. By dissociating the growth factors with matrix proteins, FAP could promote the tumor microvascular generation and the growth of tumor cells, and played an important role in the invasion and metastasis of tumors \[[@B18]\]. Gong et al. \[[@B19]\] found that *miR-21* induced the expression of FAP and promoted the malignant progression of breast phyllodes tumors. Consistently, Wang et al. \[[@B6]\] found that the down-regulation of FAP in oral cancer could inhibit cell propagation by activating phosphatase and tensin homology deleted on chromosome 10/phosphoinositide 3-kinase/AKT (PTEN/P13K/AKT) and Ras-extracellular signal regulated kinase (Ras-ERK) signaling pathways. Unfortunately, there was no study on how miRNAs regulated the expression of FAP in oral cancer cells.

Up to now, few researches about miRNAs' abnormity in oral cancer had been done and the current study focussed on *miR-30a-5p*/FAP function on the viability, proliferation, migration, and invasiveness of oral cancer cells.

Materials and methods {#sec2}
=====================

Clinical specimens {#sec2-1}
------------------

Sixty six oral cancer tissues and 25 adjacent normal tissues (at least 2--3 cm from the tumor margin, verified to be free of tumor) were obtained from surgical resection. Inclusion criteria were applied as described in a recent study \[[@B20]\]. In brief, patients were diagnosed with cancer of the oral cavity but did not receive radiotherapy and chemotherapy before. Written consents were confirmed. Two cohorts of human oral cancer collected at Renmin Hospital of Wuhan University in the year of 2015. All clinical specimens preserved in liquid nitrogen until RNA extraction. The present study was approved by Renmin Hospital of Wuhan University and all participants signed an informed consent agreement. All clinical information for human oral cancer tissues was presented in [Table 1](#T1){ref-type="table"}.

###### Clinicopathological Features of oral cancer tissues

  Characteristics        Oral cancer tissues (*n*=66)   Adjacent normal tissues (*n*=25)
  ---------------------- ------------------------------ ----------------------------------
  **Tissue**                                            
    Tongue               35                             12
    Bucca                16                             6
    Lip                  15                             7
  **Gender**                                            
    Male                 41                             17
    Female               25                             8
  **Age at diagnosis**                                  
    Median (range)       55 (35--78)                    55 (37--78)
    Mean ± S.D.          55 ± 10                        53 ± 15
  **TNM stage**                                         
    I                    6                              0
    II                   13                             5
    III                  17                             7
    IV                   30                             13

Cell culture {#sec2-2}
------------

Normal human oral epithelial cells (NHOECs) were obtained via primary culture: resected oral mucosa was washed with PBS, digested in Dispase II at 4°C for 24 h, and then digested in trypsin. The cells were subsequently inoculated and cultured at a density of 1 × 10^6^/30000 mm^2^. Tca-8113 and HEK-293T were purchased from Bena Culture Collection, and SCC-15, SCC-25, SCC-4 from ATCC. These cells were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640) which contained 10% FBS, 100 U/ml streptomycin, and 100 U/ml penicillin under the conditions of 37°C in 5% CO~2~ and 95% atmospheric humidity.

Cell transfection {#sec2-3}
-----------------

FAP siRNA, *miR-30a-5p* mimics, mimics control (mirVana™ miRNA Mimic, negative control \#1, catalog (Cat): 4464058), *miR-30a-5p* inhibitor and inhibitor control (Ambion® Anti-miR™ miRNA Inhibitor Negative Control \#1, Cat: AM17010) were all synthesized by Thermo Fisher Scientific, U.S.A. All sequences' information is provided in [Table 2](#T2){ref-type="table"}. PcDNA3.1-EGFP vector was purchased from Genechem Co., Ltd (Shanghai, China). Lipofectamine™ 2000 (Invitrogen, U.S.A.) was used to transfect RNA and vector.

###### Sequences for qRT-PCR, PCR, siRNAs, mimics, inhibitors

  Name                     Sequences
  ------------------------ -----------------------------------------
  *q-*FAP-F                5′-GGCACGGTATTCAAAAGTCCG-3′
  *q-*FAP-R                5′-ACCCAAGTCTTCATTTTTCCAGATG-3′
  *q-*GAPDH-F              5′-AGTAGAGGCAGGGATGATG -3′
  *q-*GAPDH-R              5′-TGGTATCGTGGAAGGACTC -3′
  *q-miR-30a-5p*-F         5′- GGGCCTGTAAACATCCTCG-3′
  *q-miR-30a-5p*-R         5′-GAATACCTCGGACCCTGC-3′
  *q-*U6-F                 5′-GGTCGGGCAGGAAAGAGGGC-3′
  *q-*U6-R                 5′- GCTAATCTTCTCTGTATCGTTCC-3′
  FAP-cDNA-F               5′- CTCGAGCGCGATGAAGACTTGGGTAAAAATCG-3′
  FAP-cDNA-R               5′-GGATCCGCGCTTAGTCTGACAAAGAGAAACAC-3′
  FAP-3′UTR-WT-F           5′-CGATGCAGATGCAAGCCTG-3′
  FAP-3′UTR-WT-R           5′-GCACTTGAACTTCTGAC-3′
  FAP-3′UTR-mut-F          5′-AGAAGTTCAAGCTACTGGTACTCTGTG-3′
  FAP-3′UTR-mut-R          5′-CACAGAGTACCAGTAGCTTGAACTTCT-3′
  FAP siRNA                5′-GCACUCACACUGAAGGAUATT-3′
  siRNA control            5′-GCAACACAGUCGGAUCAUATT-3′
  *miR-30a-5p* mimics      5′-UGUAAACAUCCUCGACUGGAAG-3′
  Mimics control           5′-UAGAUACGAUCCGAACUUGCAU-3′
  *miR-30a-5p* inhibitor   5′-CUUCCAGUCGAGGAUGUUUACA-3′
  Inhibitor control        5′-ACAUAGGGCCCAUGCUAACUGC-3′

Abbreviations: cDNA, the full length of *FAP* mRNA which can express FAP protein; F, forward; *q*, primers used for qRT-PCR; R, reverse; 3′UTR-mut, deletion mutation of wild-FAP 3′-UTR; 3′UTR-WT, wild-FAP 3′-UTR.

RNA extraction and RT-qPCR {#sec2-4}
--------------------------

According to the instructions of reverse transcription (RT) kit (Promega, Madison, WI, U.S.A.), we extracted total RNA from frozen clinical specimens with TRIzol reagent and reversed RNA into cDNA. Chain amplification was then carried out based on qPCR kit (Invitrogen, Carlsbad, CA, U.S.A.). U6 and GAPDH were the used as loading control. The primers (Sangon, Shanghai, China) sequences were displayed in [Table 2](#T2){ref-type="table"}.

Western blot analysis {#sec2-5}
---------------------

The total protein was extracted from transfected cells and the concentration was subsequently quantitated using BCA protein quantitative method. After SDS/PAGE protein electrophoresis, proteins were transferred on to a PVDF membrane and blocked with 5% skim milk for 2 h. Primary antibodies of FAP and GAPDH (Abcam, Cambridge, MA, U.S.A.) were incubated overnight at 4°C. Then, HPR-conjugated secondary antibodies were incubated for 1 h. The film was then developed using ECL.

Dual luciferase reporter gene assay {#sec2-6}
-----------------------------------

FAP 3′-UTR wild-type and mutant were amplified with FAP cDNA. The sequences were amplified using primers provided in [Table 2](#T2){ref-type="table"}. Then pGL3 plasmids (both wild-type and mutated) were inserted into the UTRs. Then, the recombined 3′-UTR pGL3 plasmids were transiently transfected into HEK-293T cells together with *miR-30a-5p* mimics or mimics control by Lipofectamine™ 2000 according to the manufacturer's instructions.

Biotin-coupled miRNA capture {#sec2-7}
----------------------------

The biotin-coupled miRNA pulldown was performed as previously described \[[@B21]\]. In brief, we labeled *miR-30a-5p* mimics and mimics control with biotin at the 3′ end and then transient transfected the biotin-labeled sequence into HEK-293T cells which stably expressed FAP (stably transfection of pCDNA3.1-FAP) at a final concentration of 30 nM for 24 h. Total RNA was separated and incubated with streptavidin beads (Life Technology) to capture the biotin-coupled miRNA mimics. The abundance of *FAP* mRNA in bound fractions was evaluated by RT-qPCR.

MTT assay {#sec2-8}
---------

Transfected cells in the logarithmic growth phase were seeded in a 96-well plate with a density of 5 × 10^3^/ well. MTT (10 mg/ml) was added to each well and cultured for another 4 h. Then 100 µl DMSO was added to each well. Optical absorbance at a wavelength of 450 nm was recorded.

Colony formation assay {#sec2-9}
----------------------

Six groups of cells were inoculated on to 60-mm plates with a density of 600 per well. After being incubated for 13 days, cells were washed with PBS, fixed with 10% formaldehyde for 15 min, and stained for 30 min with Crystal Violet. Colony number for each group was observed and recorded under a microscope.

Wound healing assay {#sec2-10}
-------------------

Cells were incubated in a six-well plate at a density of 2 × 10^5^ per well. After the cells reached a confluence of 80%, we used a 100-µl sterile micropipette to scratch a straight line on the surface of each well. Cells were first washed with PBS, and then incubated in Dulbecco's modified Eagle's medium (DMEM) that contained 2% FBS. The plate was photographed at 0 and 24 h and migration rate was measured with an inverted microscope.

Invasion assay {#sec2-11}
--------------

Transwell chambers were covered with Matrigel (20 μl, 0.5 g/l) and placed on a 24-well plate. Lower chambers were added with RPMI-1640 that contained 10% FBS, while upper chambers were filled with 200 μl cell suspension. After being incubated for 36 h, invading cells were fixed in 4% paraformaldehyde and stained with 0.1% Crystal Violet. Twelve randomly selected fields were photographed and cells were counted under a microscope.

Statistical analysis {#sec2-12}
--------------------

GraphPad Prism 6.0 was used to conduct statistical analysis and plotting. All the data were presented as mean ± S.D. Differences between the two groups were analyzed using Mann--Whitney U test. Comparisons amongst groups were performed with ANOVA. *P*\<0.01 was considered to have significant statistical difference. MTT and invasion assay used three wells in each group and all were performed in triplicate for accuracy.

Results {#sec3}
=======

*MiR-30a-5p* was lowly expressed while FAP was highly expressed in oral cancer {#sec3-1}
------------------------------------------------------------------------------

To evaluate the expression level of *miR-30a-5p* and FAP in oral cancer patients, we collected 66 oral cancer tissues and 25 adjacent non-cancerous tissues. On an average, *miR-30a-5p* expression in cancer tissues was 0.35-times as that of the adjacent tissues, while *FAP* mRNA expression in cancer tissues was 3.3-times higher than adjacent tissues (*P*\<0.05, [Figure 1](#F1){ref-type="fig"}A,B). Besides, *miR-30a-5p* and FAP were negatively correlated in adjacent tissues as well as in oral squamous carcinoma cells (OSCCs) as shown in [Figure 1](#F1){ref-type="fig"}C,D (*P*\<0.05). Western blot confirmed that FAP was highly expressed in cancer tissues ([Figure 1](#F1){ref-type="fig"}E). Besides, FAP was also highly expressed in different OSCC cell lines Tca-8113, SCC-4, SCC-15, SCC-25 compared with normal cell line NHOEC ([Figure 1](#F1){ref-type="fig"}F). We further detected RNA expression of *miR-30a-5p* in different cell lines, amongst which Tca-8113 and SCC-15 cells showed lower expression ([Figure 1](#F1){ref-type="fig"}G); and mRNA level of FAP in different cell lines was most highly up-regulated in Tca-8113 and SCC-15 cells ([Figure 1](#F1){ref-type="fig"}H).

![MiR-30a-5p was lowly expressed while FAP was highly expressed in oral cancer\
(**A**) MiR-30a-5p mRNA was significantly lower in OSCC cells than normal ones. (**B**) *FAP* mRNA was significantly lower in OSCC cells than normal ones. (**C**) MiR-30a-5p was negatively correlated with FAP in normal cells. (**D**) MiR-30a-5p was negatively correlated with FAP in OSCC cells. (**E**) FAP was highly expressed in OSCC cells by Western blot. (**F**) FAP was highly expressed in all OSCC cell lines including Tca-8113, SCC-4, SCC-15, and SCC-25. (**G**) MiR-30a-5p was lowly expressed in all OSCC cell lines and most significant changes were detected in Tca-8113 and SCC-15 group. (**H**) FAP was lowly expressed in all OSCC cell lines and most significant changes were detected in Tca-8113 and SCC-15 group; \*\*, *P*\<0.01, represented significant differences compared with NHOEC group.](bsr-38-bsr20171027-g1){#F1}

*MiR-30a-5p* directly targetted FAP and suppressed its expression {#sec3-2}
-----------------------------------------------------------------

TargetScan (<http://www.targetscan.org/>) predicted the targetting sites for *miR-30a-5p* and FAP 3′-UTR, and HEK-293T cells, which served as a vector, were co-transfected with pGL-3FAP-WT, pGL-3FAP-MUT, *miR-30a-5p* mimics, and mimics control. The relative luciferase activity of pGL-3-FAP-WT group was significantly lower than pGL-3-FAP-MUT group, indicting a direct target relationship between miR-30a-5p and FAP (*P*\<0.01, [Figure 2](#F2){ref-type="fig"}A). In addition, HEK-293T cells stably expressing FAP after FAP cDNA transfection were transiently transfected with biotinylated *miR-30a-5p* (Bi-*miR-30a-5p*) or biotinylated non-specific miRNA (Bi-NC). RT-qPCR analysis of FAP mRNA level indicated FAP mRNA was 3.5-times higher than that in Bi-NC group (normalized as 1) (*P*\<0.05, [Figure 2](#F2){ref-type="fig"}B), further verifying the target relationship. Cells were divided into eight groups: control (no treatment), NC (Lipofectamine™ 2000 treatment), mimics (*miR-30a-5p* mimics), inhibitor (*miR-30a-5p* inhibitor), FAP (pcDNA3.1-FAP), siFAP (FAP siRNA), mimics + siFAP (*miR-30a-5p* mimics and FAP siRNA), and mimics + FAP (*miR-30a-5p* mimics and pcDNA3.1-FAP), each group was compared with the control (normalized as 1). At 48 h after transfection, *miR-30a-5p* mRNA expressions drastically increased in *miR-30a-5p* mimics group, *miR-30a-5p* mimics + siFAP group and *miR-30a-5p* mimics + FAP group (all *P*\<0.01), while it decreased in *miR-30a-5p* inhibitor group (*P*\<0.05). *FAP* mRNA expressions significantly increased in *miR-30a-5p* inhibitor group and FAP group while decreased in mimics group, siFAP group, and *miR-30a-5p* mimics + siFAP group (all *P*\<0.01, [Figure 2](#F2){ref-type="fig"}C,D). Protein expression changes in *miR-30a-5p* mimics + siFAP and *miR-30a-5p* mimics + FAP group also confirmed that FAP siRNA or cDNA had no effect on *miR-30a-5p* expression but conversely *miR-30a-5p* could decrease FAP expression ([Figure 2](#F2){ref-type="fig"}E).

![*MiR-30a-5p* directly targetted FAP and suppressed its expression\
(**A**) TargetScan predicted the target site of FAP at 173--180. Luciferase activity confirmed the direct target relationship between *miR-30a-5p* and FAP. (**B**) *FAP* mRNA expression was significantly higher in Bi-*miR-30a-5p* group than in Bi-NC group after biotin-coupled miRNA sedimentation by qRT-PCR. (**C**) *MiR-30a-5p* mRNA expression increased in *miR-30a-5p* mimics, *miR-30a-5p* mimics + siFAP, and *miR-30a-5p* mimics + FAP groups while decreased in *miR-30a-5p* inhibitor group. (**D**) *FAP* mRNA expression decreased in *miR-30a-5p* mimics, siFAP, and *miR-30a-5p* mimics + FAP groups while increased in *miR-30a-5p* inhibitor group and FAP groups. (**E**) FAP protein expression decreased in *miR-30a-5p* mimics, siFAP, and *miR-30a-5p* mimics + FAP groups while increased in miR-30a-5p inhibitor group and FAP groups; \*\*, *P*\<0.01, represented significant differences compared with control group.](bsr-38-bsr20171027-g2){#F2}

*MiR-30a-5p* suppressed the cell proliferation of oral cancer cells via down-regulating FAP {#sec3-3}
-------------------------------------------------------------------------------------------

MTT assay revealed that *miR-30a-5p* mimics, FAP siRNA, *miR-30a-5p* mimics + FAP siRNA could significantly reduce the cell viability of both Tca-8113 and SCC-15 cells, but *miR-30a-5p* inhibitor and FAP could both increase the cell viability. Therefore, FAP may accelerate cell proliferation which could reversely be reduced by *miR-30a-5p* ([Figure 3](#F3){ref-type="fig"}A). Clone formation assay validated the same conclusion considering smaller colony number in *miR-30a-5p* mimics, FAP siRNA, *miR-30a-5p* mimics + FAP siRNA groups, and larger colony number in *miR-30a-5p* inhibitor and FAP groups ([Figure 3](#F3){ref-type="fig"}B).

![*MiR-30a-5p* suppressed the cell proliferation of oral cancer cells via down-regulating FAP\
(**A**) *MiR-30a-5p* mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA could significantly reduce the cell viability of both Tca-8113 and SCC-15 cells, but miR-30a-5p inhibitor and FAP could both increase the cell viability. (**B**) Colony number was smaller in *miR-30a-5p* mimics, FAP siRNA, *miR-30a-5p* mimics + FAP siRNA groups but larger in *miR-30a-5p* inhibitor and FAP groups; \*\*, *P*\<0.01, represented significant differences compared with control group.](bsr-38-bsr20171027-g3){#F3}

*MiR-30a-5p* suppressed the migration and invasion of oral cancer cells via down-regulating FAP {#sec3-4}
-----------------------------------------------------------------------------------------------

Smaller wound healing area indicated stronger migration ability, therefore, *miR-30a-5p* mimics, FAP siRNA, *miR-30a-5p* mimics + FAP siRNA groups shared weaker migration ability, while *miR-30a-5p* inhibitor and FAP group shared stronger invasion ability (all *P*\<0.01, [Figure 4](#F4){ref-type="fig"}A). Invasion ability was valued by invading cells in Tca-8113 and SCC-15 cell lines. As shown in [Figure 4](#F4){ref-type="fig"}B, *miR-30a-5p* mimics, FAP siRNA, *miR-30a-5p* mimics + FAP siRNA groups showed weaker invasion ability, while *miR-30a-5p* inhibitor and FAP groups displayed stronger invasion ability.

![*MiR-30a-5p* suppressed the migration and invasion of oral cancer cells via down-regulating FAP\
(**A**) *MiR-30a-5p* mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA groups shared weaker migration ability, while *miR-30a-5p* inhibitor and FAP group shared stronger invasion ability. (**B**) *miR-30a-5p* mimics, FAP siRNA, *miR-30a-5p* mimics + FAP siRNA groups showed weaker invasion ability, while *miR-30a-5p* inhibitor and FAP groups displayed stronger invasion ability; \*\*, *P*\<0.01, represented significant differences compared with control group.](bsr-38-bsr20171027-g4){#F4}

Discussion {#sec4}
==========

In the present study, we confirmed that *miR-30a-5p* directly targetted FAP and down-regulated FAP expression in OSCC cell lines. Furthermore, *miR-30a-5p* suppressed the proliferation, migration, and invasion by inhibiting FAP in functional experiments.

*MiR-30a* family, namely *miR-30a-3p* and *miR-30a-5p*, plays a tumor-suppressive role in various cancers, including breast cancer, hepatocellular carcinoma, lung cancer, glioblastoma, colon cancer, and prostatic cancer \[[@B13],[@B14],[@B22]--[@B25]\]. Besides, *miR-30a-5p* has been reported to function in prediction and diagnosis for diverse cancers, such as renal cell carcinoma, low histological grade chondrosarcoma, giant cell tumor, breast cancer, prostate cancer, and lung cancer \[[@B13],[@B26]--[@B31]\]. Some researchers have revealed its negative association with tumor progression. For example, Tang et al. \[[@B23]\] discovered that *miR-30a-5p* was lowly expressed in lung cancer and negatively associated with tumor size, lymphatic metastasis, histological classification, clinical TNM stage, pathological progression, and overall survival rate, as a tumor inhibitor. In the present study, miR-30a-5p was substantially down-regulated in OSCC tissues, suggesting that it might be a tumor suppressor during OSCC progression.

The relationship between *miR-30a-5p* and target genes has been reported previously. For instance, Yu et al. \[[@B32]\] reported that autophagy-related gene (ATG) could be directly regulated by *miR-30a-5p* in the chronic myelogenous leukemia cells. Ouzounova et al. \[[@B33]\] found that overexpression of *miR-30a-5p* significantly down-regulated AVEN (apoptosis and caspase activation inhibitor), which partly contributed to the reduction in breast cancer progression. Chen et al. \[[@B34]\] found that *miR-30a-5p* inhibited cell migration and invasion by decreasing the expression of vimentin expression in breast cancer. Increasing evidence indicated that astrocyte elevated gene-1 (AEG-1) could be a potential target gene of *miR-30a-5p* in breast cancer, lung cancer, and hepatocellular carcinoma \[[@B35]--[@B37]\]. We herein discovered that *miR-30a-5p* could directly bind to FAP in OSCCs and activate a series of cell activities including propagation, migration, and invasion.

Previous researchers found that FAP was selectively up-regulated on the surface of cancer-related fibroblasts adjacent to epithelial cancers, such as colorectal, pancreatic, breast, and lung cancers \[[@B38]--[@B40]\]. We also found that FAP was significantly up-regulated in OSCCs and tissues, indicating that FAP might be an oncogene for OSCC pathogenesis. *MiR-30a-5p* could partially inhibit FAP expression. FAP knockdown hindered the viability, proliferation, migration, and invasiveness in OSCC cells. The present study then verified that *miR-30a-5p* could inhibit tumorigenesis by directly regulating FAP.

In spite of all findings, there exist some limitations in the present study. Further experiments to confirm the function of *miR-30a-5p*/FAP *in vivo* were omitted due to lack of time. The underlying mechanism of the inhibition still remains to be investigated. Therefore, more discussion could be proceeded for a thorough understanding of *miR-30a-5p*/FAP mechanism in oral cancers.

To sum up, the present study confirmed that *miR-30a-5p* directly targetted FAP and inhibited cell viability, proliferation, migration, invasiveness of OSCC cells, revealing *miR-30a-5p* as a suppressor in OSCC tumorigenesis and progression.
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